Translational Strategies for Tissue Engineering

Achieving Commercial Success with Tissue Engineered Products

31st October – 2nd November, Boston

Book early and save up to $400

Benefits of attending

- Devise effective strategies for **patent protection that preserve the commercial value of your technologies**
- Discover creative **approaches to securing investment, long-term funding** and **how to make your company an attractive investment opportunity**
- **Meet and engage with the pioneers of the tissue engineering space** and benefit from their insights and experience
- Learn how to **effectively market a tissue engineered product and understand your physician target**
- Gain **market perspectives on the regenerative medicine sector** and identify the latest opportunities for growth and product development
- Get updated on new **licensing strategies following changes to the reimbursement landscape**

Workshops: 31st October 2011

A) Overcoming Process & Manufacturing Challenges in Development of Tissue Engineered Products

Sarah Callens, Process Development Specialist, Regenerative Medicine & Cellular Therapies, **eXmoor Pharma Concepts**

B) Navigating the Global Regulatlory Pathways for Tissue Engineered Products

Scott Burger, Principal, **Advanced Cell & Gene Therapy**

Media partners

Stem Cell News

cell therapy group — REGENMED INDUSTRY CONSULTING

Expert Reviews Medical Devices www.expert-reviews.com

Regenerative Medicine

espicom BUSINESS INTELLIGENCE

22 expert speakers including

Hans Keirstead
Chairman
California Stem Cell

Ian Harris
Director, Cell Platform
Centocor

Geoff MacKay
President & CEO
Organogenesis

David Hurley
Global Medical Lead, Musculoskeletal Group, **Pfizer**

Todd McAllistar
CEO
Cytograft Tissue Engineering

Mitchell Seyedin
CEO
ISTO Technologies

Douglas Armstrong
Senior Managing Director
Lifetech Capital

Michael West
CEO
BioTime

Gaye Bok
Executive in Residence
Excel Venture Management

Lee Buckler
Managing Director
Cell Therapy Group

Tel: +1 212 537 5898 Email: info@hansonwade.com

www.tissue-engineering-conference.com

hansonwade

Translational Strategies for Tissue Engineering | Boston | 31st Oct – 2nd Nov 2011

Benefits of attending

The therapeutic promise of tissue engineering has captivated the industry. But in order to fully capitalize there need to be robust strategies for turning this great science into profitable and sustainable businesses.

While an increasing number of deals are being done in the tissue engineering space, there is still no clear commercialization model or exit pathway. Everyone aspires to mimic the recent successes of **Advanced Biohealing**, **Dendreon**, **or Organogenesis**, but there are a variety of other commercialization and financing pathways that can be pursued to achieve self-sustaining revenues and an eventual exit.

Hanson Wade's **Translational Strategies for Tissue Engineering** meeting is the world's first and only conference dedicated to tackling the challenges of commercializing tissue products.

Join the industry pioneers from **Geron**, **J&J**, **Celgene**, **Biotime**, **Organogenesis**, **TEI Biosciences**, **Histogenics**, **ISTO Technologies**, **Cook Biotech**, **Axogen**, **CIRM** and many others to learn how to accelerate progress in this burgeoning sector.

Not-to-miss sessions:

1. Veteran **Hans Keirstead** will detail emerging trends and opportunities in development of stem cell based products so you can take advantage of past experiences
2. **Nemours** will assess the benefits and limitations of both synthetic and natural scaffolds and see what this means for your device
3. **Organogenesis CEO Geoff MacKay** will highlight CMC challenges and process issues in the manufacture of wound healing products
4. Hear **Lee Buckler's** overview of how the tissue engineering space will expand and identify where your technology fits in
5. Get expert advice from **Lifetech Capital** and **Excel Medical Ventures** on how to raise capital and demonstrate the business case for development and investment
6. Learn how to refine your clinical strategy from those already there and accelerate your commercial development with thoughts from **Cytograft**, **Axogen** and **Histogenics**
7. **Foley & Lardner** explain the legalities of device patenting so you can ensure your innovation is protected
8. See big pharma's efforts to translate research into tissue engineered products with talks from **Pfizer** and **Centocor**

Who should attend?

Translational Strategies for Tissue Engineering is the first meeting of its kind designed to bring together business and scientific leaders from tissue engineering companies and translational laboratories to specifically address challenges around commercialization. This meeting is for:

- C-level biotech executives
- Scientists leading cell therapy, stem cell and regenerative medicine efforts
- VPs, directors and heads of business development
- Tissue engineers and medical device specialists
- Heads of emerging science groups
- Investors and venture capitalists

Register now to engage with the leading business and scientific minds in this field.

LinkedIn Search groups for: **Commercial Tissue Engineering** to join the online community.

Hear what previous Hanson Wade attendees have to say

"A great place to get the very latest information and networking."
Pfizer

"This was a highly informative conference in an exploding field… It brought together in one place all of the major people working in this field"
Forward Ventures

"This was a good event for us. The size of the meeting allowed us time to really engage with the attendees rather than just the few minutes we might have at a tradeshow."
Lonza

"Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues…"
Sanofi

"Honestly, the event had everything. Good talks, good speakers, good networking, good venue and good schedule. Keep running events like this and Crucell will be in regular attendance at your events"
Crucell

"First class meeting – incredible opportunity to meet directly with a broad range of decision makers in this growing field"
Quanta Biodesign

Tel: +1 212 537 5898 Email: info@hansonwade.com
www.tissue-engineering-conference.com

hansonwade

Translational Strategies for Tissue Engineering | Boston | 31st Oct – 2nd Nov 2011

Keynote Session Networking Session

Day 1 — 1st November 2011

8.00 **Registration, Coffee and Networking**

8.55 **Chair's Opening Remarks**

9.00 **Market Insight: A Global Landscape Perspective of Tissue Engineering Development and Commercialization Activities**

- A global overview of the commercialization and clinical development of tissue engineered products
- The five trends that may be critical to the commercial viability of those in the sector moving forward
- A guide to the companies to pay close attention to

Lee Buckler, Managing Director, **Cell Therapy Group**

9.30 **Cell and Matrix: Translational Strategies in the Era of Pluripotency**

- Combining new cell types from the lab bench with novel matrices
- Achieving greater standards of identity and purity of the cellular components and safer, more appropriate matrices
- Strategies to meet these emerging criteria may prove critical to commercial success in the coming decade

Michael West, CEO, **BioTime**

10.00 **Speed Networking**

Connect with key attendees early in the meeting and make the most out of the next two days networking time

"The speed networking session was the best I have ever seen. Very successful!" **Novasep**

11.00 **Morning Refreshments**

Translating Innovations into Market Successes

11.30 **Staking Your Claim in the Biomaterials Field as a Wound Healing Pioneer**

- Target Product Profile
- CMC issues / process modifications
- Metrics to assess productivity
- Changing the standard of care

Geoff MacKay, CEO, **Organogenesis**

12.00 **Business models for Cell Therapies**

- Review of business models driven by platform technologies under development in the industry
- Case Study: Geron's development path with hESCs

David Earp, SVP, Corporate Transactions & Chief Legal Officer, **Geron**

12.30 **Is There a Correct Business Model for Tissue Engineering?**

- Pros and cons of commercializing a tissue product versus taking an exit pathway
- Gaining a commercial edge over competitor products

Robert Hariri, CEO, **Celgene Cellular Therapeutics**

1.00 **Lunch**

2.00 **Developing Soft Tissue Reconstruction Products for Wide-Spread Marketing**

- Minimizing foreign body inflammatory response
- Platform technology leads to superior gross margins
- Long shelf life and room temperature storage allow for worldwide marketing

Yiannis Monovoukas, Chairman, President & CEO, **TEI Biosciences**

2.30 **Translation: Strategies to Reach Commercialization from Research**

- Devising a clear strategy to address the technical and regulatory risks for entering the clinic
- How to manage the investment in the development program to reduce financial risk
- Case study: Minimizing risk in clinical development

Ian Harris, Director, Cell Platform, **Centocor**

3.00 **Effectively Marketing Tissue a Engineered Product: Data is Not Enough**

- Understanding the physician target
- How doctors think and learn
- Understanding medical use scenarios for a product
- Constructing the medical value proposition

David Hurley, Global Medical Lead, Musculoskeletal, **Pfizer**

3.30 **Afternoon Refreshments**

Refining Your Business Strategies

4.00 **Effectively Raising Investment Capital for Your Regenerative Medicine Company**

- Investment banking and capital strategy for companies engaged in tissue engineering
- Options in funding structures and strategies
- Key messages to be communicating to Wall Street

Douglas Armstrong, Senior Managing Director, **Lifetech Capital**

4.30 **Venture Capital Firms: How Can You Raise Long Term Funding to Sustain Development and Commercialization?**

- What makes a biotech an attractive investment prospect?
- Raising long-term funding for the development of novel therapeutics
- Emerging trends in the investment of regenerative medicine

Gaye Bok, Executive in Residence, **Excel Medical Ventures**

Defining a Regulatory Strategy and Protecting the IP of your Innovations

5.00 **Effective Patenting of Your Biomarkers and Medical Devices**

- Patent protection for preserving the commercial value of innovative technologies related to tissue engineering
- Patent biomarkers and medical devices to further commercial ventures both domestically and abroad

James Ewing, Partner, **Foley & Lardner**

5.30 Chair's Closing Remarks

7.00 **Networking Dinner**

Tel: +1 212 537 5898 Email: info@hansonwade.com
www.tissue-engineering-conference.com

hansonwade

Translational Strategies for Tissue Engineering | Boston | 31st Oct – 2nd Nov 2011

Keynote Session Networking Session

Day 2 — 2nd November 2011

8.00 **Registration, Coffee and Networking**

8.55 **Chair's Opening Remarks**

9.00 **Emerging Industry: Clinical Development of Stem Cell Based Products**

- Production and supply of clinically relevant human cell populations
- Turning discoveries into clinical and commercial reality
- Successes and challenges facing the clinical development of stem cell based products

Hans Keirstead, Chairman, **California Stem Cell**

9.30 **The role of the California Institute for Regenerative Medicine in developing tissue engineered products.**

- Provide an update on CIRM's current footprint in the tissue engineering landscape
- Introduce CIRM's funding opportunities for tissue engineered products at various stages of development
- What is CIRM doing to advance the field and facilitate translation of tissue engineered products

Kevin Whittlesey, Science Officer,
California Institute for Regenerative Medicine

Driving Commercial Value

10.00 **Achieving a Dynamic Commercialization Strategy for Cell-Based Therapies to Rebuild Diseased Cardiovascular Tissue**

- Specific strategies to reduce cash burn
- Gaining access to non-dilutive capital
- Unique licensing strategies that recognize changes in the reimbursement landscape
- Reimbursed clinical studies outside the U.S.

Todd McAllister, CEO, **Cytograft Tissue Engineering**

10.30 **Morning Refreshments**

11.00 **Devising a strategy for effective commercialisation of next generation biological constructs in advance of a regulatory approval**

- How do we manage and pay for clinical programs?
- Creative methods of generating near-term revenue without heavily relying on venture backing
- Case Study: developing a partnership to minimize financial and strategic risks associated with early programs in new therapeutic areas

Mitchell Seyedin, Chief Executive Officer,
ISTO Technologies

11.30 **Leveraging the commercial viability of biological products for soft-tissue applications**

- Harnessing social, economical, healthcare and regulatory factors to drive the translation of tissue engineering toward commercialization
- How to leverage the viability of biological products to advance a product candidate to market
- Case Study: How we leveraged Histogenics and ProChon Biotech's strengths in tissue engineering and cell therapy, post-merger, to develop a novel and competitive portfolio

Patrick O'Donnell, Chief Executive officer, **Histogenics**

12.00 **Lunch**

1.00 **Approaches to Develop and Effectively Commercialize Novel Tissue Products for the PNS**

- Case study: How AxoGen effectively manages its strategic and product development partnerships
- Successfully transitioning a privately-owned company to a public company
- Creating brand awareness and selling regenerative medical products in the US

John Engels, VP & Co-Founder, **AxoGen**

1.30 **Novel Strategies in Tissue Repair and Augmentation in Aesthetic Dermatology and General Surgical Applications**

- Implications of the commercial, regulatory and development issues on the in-house portfolio
- Developing biologic response modifiers and new tissue matrices

Reinhard Koenig, CEO, **Glycotex**

2.00 **Propelling the commercialization of autologus cell therapies for the treatment of congestive heart failure**

- Determining the appropriate infrastructure for each stage of product development and testing
- Establishing timelines and meeting budget demands
- Ensuring patient safety and financial security in the path the commercialization

Kristin Comella, CSO, **Bioheart**

Optimization of Scaffold and Device Design

2.30 **Effective Development of Novel Tissue Products**

- Benefits of the advent biologic graft materials to wound healing, fistula repair, and tissue reconstruction
- Creative regulatory strategies that accelerate innovation
- Devising ideal platforms for cell, drug, and gene delivery

Michael Hiles, VP & CSO, **Cook Biotech**

3.00 **Afternoon Refreshments**

3.30 **The Use of Scaffolds in Tissue Engineering and Regenerative Medicine**

- The pros and cons of the different matrices available
- Critical considerations for implanting matrices
- Optimizing cell/matrix interactions

Paul Kemp, CEO, **Intercytex**

4.00 **Synthetic Versus Naturally Derived Scaffolds**

- Encouraging functional tissue architecture
- How is the cell phenotype affected
- Assessing the characteristics different tissue geneses

Robert Akins, Head, Tissue Engineering & Regenerative Medicine, **Nemours**

4.30 Chair's Closing Remarks

Tel: +1 212 537 5898 Email: info@hansonwade.com
www.tissue-engineering-conference.com

hansonwade

Translational Strategies for Tissue Engineering | Boston | 31st Oct – 2nd Nov 2011

Workshop A: Overcoming Process & Manufacturing Challenges in Development of Tissue Engineered Products

Date: 31st October 2011
Time: 10am-1pm

Tissue engineering and regenerative medicine are interdisciplinary fields that apply principles of engineering and life sciences to develop biological substitutes, typically composed of biological and synthetic components, that restore, maintain or improve tissue function. Process development, manufacture and scale-up of novel tissue products is an established challenge in the commercialization of tissue engineered products.

Based on experience working with other leading regenerative medicine companies eXmoor Pharma will provide tailored expertise to workshop attendees. By the end of this workshop you will be able to:

- See how to **transfer process & analytical development to manufacture**
- **Model and develop improved strategies** for future manufacturing processes
- Ensure **manufacturing options fit with strategic objectives**
- Make sure your manufacturing **process is robust and GMP compliant**
- Guarantee processes, equipment, and facilities are **designed appropriately**

This workshop will provide an introduction for those new to the field and act as stimulation for those with more experience. Questions, comments and thoughts are welcomed in advance or on the day.

Workshop leader

Sarah Callens
Process Development Specialist, Regenerative Medicine & Cellular Therapies
eXmoor Pharma Concepts

Sarah Callens works as a Process Development Specialist for eXmoor Pharma Concepts ltd. With 10 years of experience in process development of cellular therapies and regenerative medicinal products her clients include, Cell Medica, ReNeuron, Organogenesis, as well as academic groups in Guy's and St Thomas Trust, and Queen Mary University. Sarah aids the development, translation and improvement of both clinical stage and commercial products. Prior to eXmoor, Sarah has held roles at ReNeuron, Onyvax, and Stryker Biotech.

Sarah is a member of the Manufacturing Advisory Committee for the BioIndustries Association, and actively involved in the ATMP Manufacturing Community.

Workshop B: Navigating the Global Regulatory Pathways for Tissue Engineered products

Date: 31st October 2011
Time: 2pm-5pm

The regulatory environment for tissue engineered products reflects the unique challenges of these novel biologics. Worldwide, a risk-based approach to regulation is common on the premise that these products present a greater risk of adverse clinical outcome and require more control and more stringent regulation and oversight.

This workshop will tackle a variety of regulatory and operational challenges and potential risks, as well as the nter-individual variability and biological heterogeneity hamper product characterization and definition

The inability to fully characterize these biological products has led regulators to emphasize manufacturing process control and monitoring as a means of reducing risk, implementing the need for GMPs and GTPs.

- Review the **regulatory pathway and expectations for cellular therapy products**
- Discuss **common regulatory and operational obstacles** and how to avoid them
- Review the global regulatory environment, including **US FDA**, **EMA** and **Asian agencies**
- **Assess the risk-based regulatory approach**, and the role of risk evaluation
- **Example scenarios will be discussed**

Workshop leader

Scott R. Burger
Principal
Advanced Cell & Gene Therapy, LLC

Scott Burger is the principal of Advanced Cell & Gene Therapy, a consulting firm specializing in development and commercialization of cell, gene-, and tissue-based products for immunotherapy and regenerative medicine.

Dr. Burger has more than 20 years of experience and works with clients from industry and academia worldwide, to provide expert guidance in technology evaluation and due diligence, GMP/GTP manufacturing and characterization, process development, facility design, regulatory affairs, and strategic analysis. He received his M.D. from the Pennsylvania School of Medicine, completed postgraduate training in Laboratory Medicine, and a fellowship in Transfusion Medicine, at Washington University in St. Louis.

Dr. Burger served as medical director of the Cell Therapy Clinical Laboratory and Molecular and Cellular Therapeutics Facility at University of Minnesota, and as Vice-President of Research and Development at Merix Bioscience, a dendritic cell immunotherapy company.

Tel: +1 212 537 5898 Email: info@hansonwade.com
www.tissue-engineering-conference.com

hansonwade

Translational Strategies for Tissue Engineering | Boston | 31st Oct – 2nd Nov 2011

Speakers

Hans Keirstead
Chairman
California Stem Cell

Hans is a Professor of Anatomy and Neurobiology at the University of California, Irvine, where he led his team to develop a hESC-derived treatment for spinal cord injury, which was the first FDA-sanctioned clinical trial of human embryonic stem cells.

Ian Harris
Director, Cell Platform
Centocor

Ian is a Senior Director in the Stem Cell Organization, Johnson & Johnson Biotechnology Center of Excellence, where he is responsible for manufacturing process development and the clinical product for an allogeneic and an autologous cell therapy.

Geoff MacKay
President & CEO
Organogenesis

Geoff has been the president and CEO of Organogenesis since 2003. He also serves on the Board of Directors of the Canadian Stem Cell Network and as Vice Chairman of the Board of the Massachusetts Biotechnology Council.

David Hurley
Global Medical Lead, Musculoskeletal Group
Pfizer

David is a Plastic and Reconstructive Surgeon and the Medicines Development Group Lead for Pfizer for area of musculoskeletal diseases. He is responsible for the development of Xiapex and morphogenic protein 2.

Todd McAllistar
CEO
Cytograft Tissue Engineering

Todd is the co-founder and CEO of Cytograft Tissue Engineering. He is also the co-Director of the Center for Regenerative Medicine at the St. Joseph's Translational Research Institute in Atlanta.

Mitchell Seyedin
CEO
ISTO Technologies

Mitchell has been the President and CEO of ISTO Technologies since 2003. ISTO's products are intended to repair and regenerate damaged cartilage tissue in joints and spinal discs, and for bone regeneration in spinal fusion applications.

Douglas Armstrong
Senior Managing Director
Lifetech Capital

Douglas is the Co-Founder and Senior Managing Director of Tekesta Capital Partners. He has held several senior positions in the industry, including CEO of Aastrom Biosciences.

Michael West
CEO
BioTime

Michael is the CEO of BioTime. He was the Founder of Geron Corporation, where he managed the research collaboration that led to the first isolation of human embryonic stem and germ cells.

Gaye Bok
Executive in Residence
Excel Venture Management

Gaye has over 15 years of operating experience in strategic planning, business and product development. She received an M.B.A in Finance and International Management from MIT's Sloan School and a B.A. from Harvard.

Lee Buckler
Managing Director
Cell Therapy Group

Lee is the founder and managing director of Cell Therapy Group, Cell Therapy News and Cell Therapy Blog. He also serves on the editorial board of the journals BioProcess International and Regenerative Medicine.

Reinhard Koenig
CEO
Glycotex

Reinhard Koenig is the CEO of Glycotex. He has an extensive background in product development and commercialization strategies in tissue regeneration and augmentation applications for plastic surgery.

Paul Kemp
CEO & CSO
Intercytex

Paul is the CEO and CSO of Intercytex. He is also Chairman of Regener8 and on the editorial board of Regenerative Medicine.

Patrick O'Donnell
President & CEO
Histogenics

Patrick is the President & CEO of Histogenics. He also serves on the Board of Directors for Histogenics and Prochon BioTech, a wholly-owned subsidiary of Histogenics.

Yiannis Monovoukas
Chairman, President & CEO
TEI Biosciences

Yiannis is Chairman, President, and CEO of TEI Biosciences a privately held company that develops and commercializes novel biologic products for soft tissue repair, reinforcement, and reconstruction applications.

Jim Ewing
Partner
Foley & Lardner

James is a partner with Foley & Lardner LLP. Dr. Ewing is vice chair of the Chemical, Biotechnology & Pharmaceutical Practice and a member of the Life Sciences, Food and Nanotechnology Industry Teams.

Robert Akins
Head, Tissue Engineering & Regenerative Medicine Research
Nemours

Robert is the Head of Tissue Engineering and Regenerative Medicine Research at Nemours. Dr. Akins' laboratory focuses on the development of advanced therapies to treat acquired and congenital diseases of muscle.

Michael Hiles
VP & CSO
Cook Biotech

Michael is the Vice President for Research and CSO at Cook Biotech. Mike also holds an appointment as Adjunct Professor of Veterinary Clinical Sciences at the Purdue University School of Veterinary Medicine.

John Engels
VP & Co-Founder
Axogen

John Engels provides operational and financial leadership for AxoGen. John holds an MBA from the Wharton School of Business, and a BA from the University of Chicago.

Robert Hariri
CEO
Celgene Cellular Therapeutics

Robert, CEO of Celgene Cellular Therapeutics, is a scientist, neurosurgeon, inventor and businessman who has established himself as leader in the development of cellular and tissue therapeutics.

Kevin Whittlesey
Science Officer
California Institute for Regenerative Medicine

Kevin manages the tissue engineered product research awards at CIRM. Prior to joining the institute, he was a Commissioner's Fellow at the US FDA.

Translational Strategies for Tissue Engineering | Boston | 31st Oct – 2nd Nov 2011

Speakers

Kristin Comella
CSO
Bioheart

Kristin Comella is the CSO at Bioheart, the co-founder and CEO of Stemlogix and CSO of the Ageless Regenerative Institute. In addition, she is actively serving on multiple boards in the stem cell arena.

David Earp
SVP, Corporate Transactions & Chief Legal Officer
Geron

David Earp is senior vice president of corporate transactions and chief legal officer at Geron. Dr. Earp also serves as executive chairman of ViaGen a Texas company deploying nuclear transfer technology for animal genetics applications.

LinkedIn

Search for **Commercial Tissue Engineering**

Meet other tissue engineering professionals before the meeting.

Open to business leaders and scientists, as well as other important stakeholders, such as investors and regulators, this group will provide a platform for discussion about the issues that are halting progress.

Sponsorship opportunities

Miles Harley

If your organisation needs to raise profile, promote products and services or develop new partnership opportunities in the Tissue Engineering sector, contact:

tel: +44 (0)20 3141 8700
email: miles.harley@hansonwade.com

Working with Hanson Wade

When you work with Hanson Wade you work with a partner focussed on your success. Your investment in both time and money needs to generate a return.

Our clients want that too and that's why they work with us. They want to reach a targeted audience and eliminate wastage from their marketing activities. They work with us because we deliver results. We're proud of this fact.

Our research identifies ground breaking issues and allows you to influence industry thinking at an early stage. Our expertise is recognised and respected by the industry. And our events are focussed, leading edge and attended by people looking for knowledge before making decisions.

Attendee breakdown

Expected Audience Breakdown



Expected Geographic Breakdown



Don't forget to check out our pre-conference master classes on manufacturing and scale-up of tissue engineered products, and navigating global regulatory pathways. Both are taking place on October 31st.

See page 5 for more information.

Tel: +1 212 537 5898 Email: info@hansonwade.com
www.tissue-engineering-conference.com

hansonwade

Translational Strategies for Tissue Engineering	Boston	31st Oct – 2nd Nov 2011	Priority Code:	WEB

Register

Online: http://tissue-engineering-conference.com
Tel: +1 212 537 5898
Fax: +1 212 537 5898
Email: info@hansonwade.com

Mail:
Hanson Wade
Charter House
13-15 Carteret St
London, SW1H 9DJ

Team discounts

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Venue and accommodation

Venue
Doubletree Suites by Hilton Hotel Boston 400 Soldiers Field Road, Boston, Massachusetts, United States 02134-1893

Accommodation
Accommodation is not included in your fee. You will be sent accommodation options upon registration.

Purchase conference documentation

If you are unable to attend, you may purchase the conference documentation in soft copy for **$799**.

You will receive the documentation immediately after the conference. Documentation orders can only be processed on receipt of credit card details.

Event prices

Package	Register and pay before Friday 2nd September**	Register and Pay before Friday 30th September**	Standard Price
☐ Conference + 2 Workshops + Networking Dinner*	US$2897 (SAVE US$400)	US$2997 (SAVE US$300)	US$3097 (SAVE US$200)
☐ Conference + 1 Workshop + Networking Dinner*	US$2398 (SAVE US$300)	US$2498 (SAVE US$200)	US$2698
☐ Conference + Networking Dinner*	US$1899 (SAVE US$200)	US$1999 (SAVE US$100)	US$2099
Half day workshop		US$599	

Please select your choice of workshop: Workshop A ☐ Workshop B ☐

***To opt out of the networking dinner please tick here ☐ $100 will be discounted from your package price**

* All discount offers (including team discounts) require payment at the time of registration to receive any discount. 'Early Bird' discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

NB: There is a 40% discount available for not-for-profit organisations and academics. Please enquire for more information and to check eligibility; call +1 212 537 5898.

Delegate details

Title: Forename: Surname:

Job Title: Company/Organisation:

Email: Direct Manager:

Address:

Postcode:

Country: Direct Telephone:

Direct Fax: Mobile:

Switchboard: Signature: Date:

Payment details

Number of delegates ☐ Amount: $ _____ Conference Documentation ☐ Credit Card: ☐ Visa ☐ Mastercard ☐ Amex

Card No: ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐ Valid from: ☐☐/☐☐ Expiry Date: ☐☐/☐☐

Cardholders name:

Signature: Date:

Card billing address:

TERMS & CONDITIONS

Full payment is due on registration.Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities

Data Protection The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ

Code: 1585

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216